Five things for pharma marketers to know: Friday, May 6, 2016

1. Pharmacy benefit managers and health insurers anticipate biosimilars will cost nearly as much as biologics. Drugmakers have been raising prices on biologics as they near patent expiration, and biosimilar manufacturers are pricing drugs only slightly below their reference products. (WSJ)

2. OxyContin, Purdue Pharma's blockbuster pain pill, is coming under fire over its 12-hour pain relief claim. An investigation based on Purdue documents and other records suggests that the pill wears off hours earlier. (LAT)

3. Embroiled drugmaker Valeant Pharmaceuticals has formed a committee to oversee its pricing policies. The committee will lead by its new chief executive and chairman, Joseph Papa.

4. Regeneron said it is securing more insurance coverage of its PCSK9 inhibitor, Praluent. The drugmaker said that 74% of people with commercial insurance and 91% of those with Medicare had access to the drug. (Reuters)

5. Pfizer made a deal worth up to $911 million to develop metabolic treatments with Wave Life Sciences. The deal gives Pfizer rights to license any experimental drugs that come out of the collaboration. (Boston Globe)